Dernières nouvelles pour Co-Diagnostics (NASDAQ:CODX) Stock

Co-Diagnostics

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Co-Diagnostics Inc

The artificial intelligence industry is largely fragmented between <a href="https://www.benzinga.com/tech/25/02/43838071/microsoft-ceo-satya-nadella-warns-of-dot-com-like-ai-bubble-pushes-for-measuring-ai-impact-with-gdp-growth-self-claiming-agi-milestone-is-just-nonsensical-benchmark-hacking">many firms jockeying</a> to be on the cutting edge of the technology. Progress is often <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43600309/google-faces-rising-ai-rivals-like-baidu-and-yandex-but-analyst-sees-search-and-ad-growth-holding-strong">benchmarked against competitors</a>, as in the case of Anthropic with its new Claude 3.7 Sonnet.
A Step Forward: Anthropic, the AI startup backed by Jeff Bezos, <a href="https://www.anthropic.com/news/claude-3-7-sonnet">announced</a> the model on Monday on its website. The San Francisco-based company called it its &#8220;most intelligent&#8221; yet.
Anthropic says the model has improved capabilities for coding and front-end web development. It also allows for an &#8220;extended thinking mode&#8221; that performs better than its standard model but takes longer to return a response to a prompt.
Anthropic also noted a change in its priorities for the models&#8217; strengths: &#8220;&#8230;in developing our reasoning models, we've optimized somewhat less for math and computer science competition problems, and instead shifted focus towards real-world tasks that better reflect how businesses actually use LLMs,&#8221; the announcement said.
How it Compares: When compared against each other, large-language models are often more proficient in some tasks and less proficient in others. OpenAI, led by Sam Altman, and DeepSeek, a Hangzhou, China-based company that sent shockwaves through financial markets with its highly efficient LLM, are among Anthropic&#8217;s competitors.
Anthropic benchmarked Claude 3.7 Sonnet against OpenAI and DeepSeek&#8217;s flagship models according to its own analyses.
The model with extended thinking beats OpenAI&#8217;s o1 and o3-mini and DeepSeek&#8217;s R1 in virtually every category besides math problem-solving. In particular, Claude 3.7 Sonnet is particularly strong in coding, easily beating other models. It is also strong in graduate-level reasoning and interactions with external systems.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43924482/exclusive-3-etfs-positioned-for-microsofts-quantum-breakthrough">EXCLUSIVE: 3 ETFs Positioned For Microsoft&#8217;s Quantum Breakthrough</a></li>
</ul>
Image: Shutterstock

News

Tech

Anthropic Releases 'Most Intelligent' LLM Yet: How Does It Compare To OpenAI, Deepseek?

WIIM

V2X shares are trading higher after the company reported a year-over-year increase in Q4 adjusted EPS results and beat its revenue estimate. Also, the company issued FY25 adjusted EPS guidance above estimates.

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) sees Q1 sales of $150.000 million-$170.000 million vs $260.40 million analyst estimate.

Guidance

OPAD

Offerpad Solutions Sees Q1 Sales $150.000M-$170.000M vs $260.40M Est

Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) reported fourth-quarter financial results after the market close on Monday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/02/b43925433/tempus-reports-fourth-quarter-and-full-year-2024-results">from the quarter</a>.
Q4 Earnings: Tempus AI reported fourth-quarter revenue of $200.68 million, missing <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $203.12 million. The AI-focused precision medicine and patient care company reported a fourth-quarter adjusted loss of 18 cents&nbsp;per share, beating analyst estimates for a loss of 20 cents&nbsp;per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 35.8% year-over-year as data and services revenue grew 44.6% to $80.2 million. Genomics grew 30.6% year-over-year to $120.4 million and unit growth came in at 22.5% year-over-year.
Tempus AI said it ended the quarter with $940 million in total remaining contract value and 140% net revenue retention. The company had approximately $340.95 million in cash and equivalents at quarter&#8217;s end.
&#8220;We believe our investments in AI have positioned us well for the future, as technologies that seemed unimaginable a few short years ago increasingly allow us to make our diagnostics intelligent, helping patients live longer and healthier lives. We remain on track to achieve our key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025,&#8221; said Eric Lefkofsky, founder and CEO of Tempus AI.
Check This Out: <a href="https://www.benzinga.com/25/02/43919364/ai-meets-data-salesforce-google-collaborate-to-revolutionize-autonomous-business-agents">Salesforce &amp; Google Supercharge AI: New Partnership Unlocks Next-Gen Business Automation</a>
Guidance: Tempus AI expects full-year 2025 revenue of approximately $1.24 billion for its consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth. Analysts are looking for full-year revenue of $1.02 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. 
The company said it anticipates a full-year 2025 adjusted EBITDA of $5 million, versus a full-year adjusted EBITDA loss of $104.7 million in full-year 2024.
Management will further discuss the company&#8217;s quarterly performance on a conference call that kicks off at 4:30 p.m. ET.
TEM Price Action: <a href="http://benzinga.com/quote/ai">Tempus AI shares</a> were up more than 105% year-to-date heading into the print. The stock has seen increased attention in recent weeks since former House Speaker&nbsp;Nancy Pelosi&nbsp;disclosed the purchase of <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43097979/tempus-ai-stock-is-trading-higher-tuesday-whats-going-on">several call options</a> that don&#8217;t expire until 2026. 
Tempus AI shares were down 7.63% after hours, trading at $64 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Tempus AI.

Earnings

After-Hours Center

Movers

Tempus AI Q4 Earnings: Revenue Miss, EPS Beat, Strong Guidance, Shares Move Lower

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 12.5 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $174.27 million which beat the analyst consensus estimate of $174.24 million by 0.02 percent. This is a 27.52 percent decrease over sales of $240.46 million the same period last year.

Earnings Beats

Earnings Misses

Offerpad Solutions Q4 Adj $(0.63) Misses $(0.48) Estimate, Sales $174.27M Beat $174.24M Estimate

Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.74) by 22.97 percent. The company reported quarterly sales of $303.15 million which missed the analyst consensus estimate of $325.22 million by 6.79 percent. This is a 21.15 percent decrease over sales of $384.46 million the same period last year.

BYON

Beyond Q4 2024 Adj EPS $(0.91) Misses $(0.74) Estimate, Sales $303.15M Miss $325.22M Estimate

Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) has outperformed the market over the past 5 years by 10.76% on an annualized basis producing an average annual return of 25.91%. Currently, Ferrari has a market capitalization of $90.13 billion. 
Buying $1000 In RACE: If an investor had bought $1000 of RACE stock 5 years ago, it would be worth $3,198.28 today based on a price of $503.91 for RACE at the time of writing.
<h3>Ferrari's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740433509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

RACE

Here's How Much $1000 Invested In Ferrari 5 Years Ago Would Be Worth Today

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

RIOT

Riot Platforms In FY24 Produced 4,828 Bitcoin Down From 6,626 Bitcoin YoY

Southeast Airport Group Q4 EPADS $5.4757 Up From $4.0686 YoY

Riot Platforms (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) reported quarterly sales of $376.700 million which beat the analyst consensus estimate of $372.349 million by 1.17 percent.Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) reported quarterly sales of $376.700 million which beat the analyst consensus estimate of $372.349 million by 1.17 percent.

Riot Platforms FY24 Sales $376.700M Beat $372.349M Estimate

Chegg Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares are dropping after the company reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43925683/chegg-reports-2024-fourth-quarter-and-full-year-financial-results">details from the report. </a>
The Details: Chegg reported quarterly earnings of 17 cents per share, which met the analyst consensus estimate. Quarterly revenue clocked in at $143.48 million, which beat the analyst consensus estimate of $142.05 million and is a decrease from revenue of $187.99 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43920295/palantir-extends-losses-microsoft-slides-whats-driving-markets-monday">Palantir Extends Losses, Microsoft Slides: What&#8217;s Driving Markets Monday?&nbsp;</a>
&#8220;We made two important and connected decisions to maximize the future of our business and shareholder value. We are launching a strategic review process and filed a complaint against Google, which has unjustly retained traffic that has historically come to Chegg, impacting our acquisitions, revenue and employees,&#8221; said Nathan Schultz, CEO of Chegg. 
&#8220;As we look to stabilize Chegg&#8217;s business in 2025, we have a strong and trusted brand, millions of global subscribers, a large market opportunity, and amazing employees. Our superior product for education is verticalized, personalized, and built on a deep understanding of modern students, and we believe this year will be a turning point for Chegg,&#8221; Schultz said. 
Outlook:&nbsp;Chegg sees&nbsp;first-quarter revenue in a range of&nbsp;$114 million to $116 million, versus the $138.07 million&nbsp;analyst estimate.
CHGG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Chegg shares are down 21.79% after-hours at $1.22 Monday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit</a></li>
</ul>
Image: Shutterstock

CHGG

Chegg Stock Plunges After Q4 Revenue Falls 24%, Weak Q1 Guidance: Details

Grupo Aeroportuario del Sureste Q4 EPS MXN11.3819 Up From MXN8.457 YoY; Revenue MXN9.020M Up From MXN6.876M

FARO

FARO Technologies shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 adjusted EPS guidance above estimates.

MYGN

Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 revenue guidance below estimates.

ProAssurance shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is looking for FY2025 FFO of $0.90-$1.00 vs $0.97 analyst estimate..

Summit Hotel Properties Sees FY2025 AFFO per common share $0.90-$1.00 vs $0.97 Est

PRIM

Primoris Services shares are trading higher following better-than-expected Q4 financial results.

The Cheesecake Factory Incorporated (the "Cheesecake Factory") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) today announced its intention to offer, subject to market and other conditions, $450,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Cheesecake Factory also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $67,500,000 principal amount of notes.
The notes will be senior, unsecured obligations of The Cheesecake Factory, will accrue interest payable semi-annually in arrears and will mature on March 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. The Cheesecake Factory will settle conversions in cash and, if applicable, shares of its common stock.

Offerings

CAKE

The Cheesecake Factory  Announced Its Intention To Offer $450M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

The 2026 outlook is driven by expected volume growth from increased production and recently completed projects, and the continued realization of acquisition-related synergies.

ONEOK Expects Greater Than 15% EPS Growth And Adjusted EBITDA Growth Approaching 10% In 2026 Vs. 2025 Guidance Midpoints

Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) reported quarterly earnings of $0.20 per share which met the analyst consensus estimate. This is a 9.09 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $172.93 million which beat the analyst consensus estimate of $172.08 million by 0.49 percent. This is a 2.54 percent decrease over sales of $177.44 million the same period last year.

Summit Hotel Properties Q4 AFFO per common share $0.20, Inline, Sales $172.93M Beat $172.08M Estimate

Press Releases

Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3

Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Comments

Co-Diagnostics

Actualités

Dernières nouvelles pour Co-Diagnostics (NASDAQ:CODX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL